Shanshan Xu

Company: Bambusa Therapeutics

Job title: Chief Executive Officer

Seminars:

Evaluating Bi-Specific Antibody & Cell Engager Targets, Safety & Efficacy to Uncover Their Commercial Potential 12:10 pm

Exploring emerging classes of cell engager and bispecific therapies, evaluating target populations, including macrophages, to identify applications in wider autoimmune diseases Comparing toxicity concerns for a broad population or efficacy in more targeted populations to evaluate the safety of engager and antibody applications Evaluating the safety and efficacy of bispecific antibody & cell engagers, in…Read more

day: Day Two